Selective and specific I f inhibition with ivabradine: New perspectives for the treatment of cardiovascular disease
| Autor: | Roberto Ferrari, Claudio Ceconi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Cardiotonic Agents sinoatrial node Ischemia Diastole Cyclic Nucleotide-Gated Cation Channels heart failure Ventricular Function Left Angina Coronary artery disease angina heart rate-reducing agents Internal medicine Heart rate Internal Medicine medicine heart rate Animals Humans Drug Interactions cardiovascular diseases Myocardial infarction business.industry General Medicine Benzazepines ivabradine medicine.disease Myocardial Contraction Cardiovascular Diseases Depression Chemical Heart failure Anesthesia Cardiology If inhibition coronary artery disease Cardiology and Cardiovascular Medicine business Ivabradine medicine.drug |
| Popis: | Heart rate is a major determinant of myocardial oxygen demand and supply, and increased heart rate adversely affects the pathophysiology of myocardial ischemia. High resting heart rate is a risk factor in cardiovascular disease. The development of the heart rate-lowering agent ivabradine showed that heart rate was also an important treatment target, notably in coronary artery disease and heart failure. Indeed, heart rate reduction with ivabradine, a selective and specific I(f) inhibitor, reduces myocardial oxygen demand, increases diastolic perfusion time and improves energetics in ischemic myocardium. Ivabradine protects the myocardium during ischemia, improves left ventricular function in heart failure and reduces remodeling following myocardial infarction. It improves prognosis in patients with coronary artery disease, left ventricular dysfunction and heart rate ≥70 beats per minute, as well as in patients with heart failure and left ventricular dysfunction. Ivabradine is safe, well tolerated and can be used in combination with the main drugs for cardiovascular disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|